May 10, 2023 / 11:35PM GMT
Unidentified Participant
Hello, I think that we're ready to start. So my name is [Perry Numal Lasky]. I am an analyst here at Bank of America, and Jason Gerberry team covers SMid Biotech. I'm pleased to introduce our next speaker Lyra Therapeutics. This is CEO, and I'm here with our CEO, Maria Palasis. And Maria, I'll turn it over to you for a presentation.
Maria Palasis - Lyra Therapeutics Inc - President, Chief Executive Officer, Director
Well, thank you, Perry. Thank you for the introduction and the invitation to present today is really an exciting time at Lyra right now. We've got two products in development, and we have some clinical trial readouts that are coming out very soon here, first one at the end of the year and then another one soon after in the first half of 2024. So Lyra has developed two products to treat chronic rhinosinusitis. And we're actually really proud to be one of the few companies that is developing products for this disease. Chronic rhinosinusitis is an inflammatory disease similar to psoriasis, eczema, but it's localized in the sinuses. And
Lyra Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 11, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers